Clinical Trials
4 trialsNCT03660826 2026-06-02
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04739800 2026-05-29
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02345265 2026-05-28
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02893917 2026-05-28
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting